Title: Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for extensive-stage small cell lung cancer, the RAPTOR trial

Principal Investigator: Quynh-Nhu Nguyen, NRG Oncology

Description: Investigators are conducting a phase 2/3 trial to test the efficacy of adding radiation therapy (RT) to atezolizumab in patients with extensive-stage small-cell lung cancer (SCLC).


Continue Reading

In the phase 2 component of the trial, researchers will compare atezolizumab plus RT with atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of SCLC that has spread to other parts of the body. 

The phase 3 part of the trial will compare overall survival (OS) in patients randomly assigned to receive atezolizumab plus RT or atezolizumab alone. 

The primary outcome measures include progression-free survival (PFS) and OS. Key secondary endpoints include the incidence of adverse events and PFS in patients with 1-3 distinct visible tumors.

To be eligible for this study, patients must have a pathologically proven diagnosis of extensive-stage SCLC. For a complete list of eligibility criteria, please see the reference.

Status: Recruiting

This study is sponsored by the National Cancer Institute (NCI) in collaboration with NRG Oncology.

Reference

Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for extensive stage small cell lung cancer, the RAPTOR trial. ClinicalTrials.Gov Identifier: NCT04402788. Updated March 18, 2022. Accessed March 22, 2022. https://www.clinicaltrials.gov/ct2/show/NCT04402788